Progressive myoclonic epilepsies: Review of clinical, molecular and therapeutic aspects

Journal of Neurology

Volumn 257, Issue 10, 2010, Pages 1612-1619

  De Siqueira, Luis Felipe Mendonça ^a  

^a FEDERAL UNIVERSITY OF MINAS GERAIS   (Brazil)

Author keywords

Epilepsy; Lafora; MERRF; Myoclonus; NCL; Unverricht

Indexed keywords

CARBAMAZEPINE; CARNITINE; CLONAZEPAM; CYSTATIN B; ETIRACETAM; LAMOTRIGINE; MITOCHONDRIAL DNA; PHENYTOIN; PIRACETAM; UBIDECARENONE; VALPROIC ACID; ZONISAMIDE; PROTEIN TYROSINE PHOSPHATASE 1B;

ATAXIA; AUTOSOMAL RECESSIVE INHERITANCE; BRAIN ATROPHY; BRAIN RADIOGRAPHY; CEREBELLUM ATROPHY; CEREBELLUM DISEASE; CHEMICAL ANALYSIS; CHROMATOGRAPHY; CHROMOSOME 11P; CHROMOSOME 12P; CHROMOSOME 21Q; CHROMOSOME 6P; CHROMOSOME 6Q; CLINICAL FEATURE; CLN3 GENE; CLN4 GENE; DEMENTIA; DENTATORUBROPALLIDOLUYSIAN ATROPHY; DISEASE COURSE; DISEASE EXACERBATION; DISEASE SEVERITY; DISORDERS OF MITOCHONDRIAL FUNCTIONS; ELECTROENCEPHALOGRAPHY; ELECTRON MICROSCOPY; ENZYME REPLACEMENT; EPILEPTIC DISCHARGE; EXTRACHROMOSOMAL INHERITANCE; GENE; GENE MUTATION; GENE THERAPY; GENERALIZED EPILEPSY; GENETIC ASSOCIATION; GENETIC VARIABILITY; GRAND MAL SEIZURE; HETEROPLASMY; HUMAN; KUPFFER CELL; MENTAL DETERIORATION; MERRF SYNDROME; MOLECULAR GENETICS; MUSCLE BIOPSY; MYOCLONUS; MYOCLONUS EPILEPSY; MYOCLONUS SEIZURE; NEURONAL CEROID LIPOFUSCINOSIS; NUCLEAR MAGNETIC RESONANCE IMAGING; OPHTHALMOLOGY; OPHTHALMOSCOPY; PREVALENCE; PRIORITY JOURNAL; PROGNOSIS; PROTEIN FUNCTION; PSYCHOMOTOR DEVELOPMENT; QUALITY OF LIFE; REVIEW; SIALIDOSIS; TONIC CLONIC SEIZURE; URINALYSIS; CLASSIFICATION; GENETICS; METHODOLOGY; PATHOLOGY; PATHOPHYSIOLOGY; SLOW MUSCLE FIBER;

ELECTROENCEPHALOGRAPHY; HUMANS; MUSCLE FIBERS, SLOW-TWITCH; MYOCLONIC EPILEPSIES, PROGRESSIVE; PROTEIN TYROSINE PHOSPHATASE, NON-RECEPTOR TYPE 1;

EID: 78650240097     PISSN: 03405354     EISSN: 14321459     Source Type: Journal    
DOI: 10.1007/s00415-010-5641-1     Document Type: Review

References (66)

1. Shahwan A, Farrell M, Delanty N (2005) Progressive myoclonic epilepsies: a review of genetic and therapeutic aspects. Lancet Neurol 4:239-248
2. Jorge CL, Valerio RMF (2003) Epilepsias mioclônicas pro-gressivas. In: Manreza ML, Grossmann RM, Valério RM, Guilhoto LM (eds) Epilepsia na infância e adolescência. Lemos Editorial, São Paulo, pp 171-188
3. Berkovic SF, Cochius J, Andermann E, Andermann F (1993) Progressive myoclonus epilepsies: clinical and genetic aspects. Epilepsia 3:S10-S30
4. Unverricht H (1891) Die myoclonie. Franz Deuticke, Leipzig
5. Lundborg H (1903) Die progressive myoclonus-epilepsie (Unverricht's Myoclonie). Almqvist and Wiksell, Uppsala
6. Norio R, Koskiniemi M (1979) Progressive myoclonus epilepsy: genetic and nosological aspects with special reference to 107 Finish patients. Clin Genet 15:382-398
7. Ramachandran N, Girard JM, Turnbull J, Minassian BA (2009) The autosomal recessively inherited progressive myoclonus epilepsies and their genes. Epilepsia 50(supl5):29-36
8. Pennacchio LA, Lehesjoki AE, Stone NE, Willour VL, Virtaneva K, Miao J et al (1996) Mutations in the gene encoding cystatin B in progressive myoclonus epilepsy (EPM1). Science 271:1731-1734
9. Lehesjoki AE (2002) Clinical features and genetics of Unverricht-Lundborg disease. Adv Neurol 89:193-197
10. Kyllerman M, Sommerfelt TK, Hedstrom A, Wennergren G, Holmgren D (1991) Clinical and neurophysiological development of Unverricht-Lundborg disease in four Swedish siblings. Epilepsia 32:900-909
11. Mascalchi M, Michelucci R, Cosottini M et al (2002) Brainstem involvement in Unverricht-Lundborg disease (EPM1): an MRI and 1H MRS study. Neurology 58:1686-1689
12. Lehesjoki AE, Koskiniemi M, Sistonen P et al (1991) Localization of a gene for progressive myoclonus epilepsy to chromosome 21q22. Proc Natl Acad Sci USA 88:3696-3699
13. Turk V, Bode W (1991) The cystatins: protein inhibitors of cysteine proteinases. FEBS Lett 285:213-219
14. Joensuu T, Lehesjoki AE, Kopra O (2008) Molecular background of EPM1 Unverricht-Lundborg disease. Epilepsia 49(4):557-563
15. Pennacchio LA, Bouley DM, Higgins KM, Scott MP, Noebels JL, Myers RM (1998) Progressive ataxia, myoclonic epilepsy and cerebellar apoptosis in cystatin B-deficient mice. Nat Genet 20:251-258
16. Shannon P, Pennacchio LA, Houseweart MK, Minassian BA, Myers RM (2002) Neuropathological changes in a mouse model of progressive myoclonus epilepsy: cystatin B deficiency and Unverricht-Lundborg disease. J Neuropathol Exp Neurol 61:1085-1091
17. Lafreniere RG, Rochefort DL, Chretien N et al (1997) Unstable insertion in the 5'-flanking region of the cystatin-B gene is the most common mutation in progressive myoclonus epilepsy type-1, EPM1. Nat Genet 15:298-302
18. Lalioti MD, Mirotsou M, Buresi C et al (1997) Identification of mutations in cystatin B, the gene responsible for the Unverricht-Lundborg type of progressive myoclonus epilepsy (EPM1). Am J Hum Genet 60:342-351
19. Berkovic SF, Mazarib A, Walid S, Neufeld MY et al (2005) A new clinical and molecular form of Unverricht-Lundborg disease localized by homozygosity mapping. Brain 128:652-658
20. Minassian BA (2001) Lafora's disease: towards a clinical, pathologic, and molecular synthesis. Pediatr Neurol 25:21-29
21. Acharya JN, Satishchandra P, Shankar SK (1995) Familial progressive myoclonus epilepsy: clinical and electrophysiologic observations. Epilepsia 36:429-434
22. Kobayashi K, Iyoda K, Ohtsuka Y, Ohtahara S, Yamada M (1990) Longitudinal clinicoelectrophysiologic study of a case of Lafora disease proven by skin biopsy. Epilepsia 31:194-201
23. Minassian BA, Lee JR, Herbrick JA et al (1998) Mutations in a gene encoding a novel protein tyrosine phosphatase cause progressive myoclonus epilepsy. Nat Genet 20:171-174
24. Ganesh S, Agarwala KL, Ueda K et al (2000) Laforin, defective in progressive myoclonus epilepsy of Lafora type, is a dual specificity phosphatase associated with polyribosomes. Hum Mol Genet 9:2251-2261
25. Chan EM, Bulman DE, Paterson AD et al (2003) Genetic mapping of a new Lafora progressive myoclonus epilepsy locus (EPM2B) on 6p22. J Med Genet 40:671-675
26. Minassian BA (2002) Progressive myoclonus epilepsy with polyglucosan bodies: Lafora disease. Adv Neurol 89:199-210
27. Luft R, Ikkos D, Palmieri G, Ernster L, Afzelius B (1962) A case of severe hypermetabolism of nonthyroid origin with a defect in the maintenance of mitochondrial respiratory control: a correlated clinical, biochemical, and morphological study. J Clin Invest 41:1776-1804
28. Engel WK, Cunningham GG (1963) Rapid examination of muscle tissue. An improved trichrome method for fresh-frosen biopsy sections. Neurology 13:919-923
29. Tsairis P, Engel W, Kark P (1973) Familial myoclonic epilepsy syndrome associated with skeletal muscle citochondrial abnormalities. Neurology 23:408
30. Fukuhara NS, Tokiguchi K et al (1980) Myoclonus epilepsy associated with ragged-red fibers (mitochondrial abnormalities) - disease entity or a syndrome? Light- and electron-microscopic studies of two cases and review of the literature. J Neurol Sci 7:117
31. Shoffner JM, Lott MT et al (1990) Myoclonic epilepsy and ragged-red fiber disease (MERRF) is associated with a mito-chondrial DNA tRNA(Lys) mutation. Cell 61:931
32. Kogelnik AM, Lott MT, Brown MD, Navathe SB, Wallace DC (1998) MITOMAP: a human mitochondrial genome database - 1998 update. Nucleic Acids Res 26:112-115
33. DiMauro S, Hirano M, Kaufmann P et al (2002) Clinical features and genetics of myoclonic epilepsy with ragged-red fibers. Adv Neurol 89:217-229
34. So N, Berkovic SF, Andermann F, Kuzniecky R, Gendron D, Quesney LF (1989) Myoclonus epilepsy and ragged-red fibers (MERRF). Electrophysiological studies and comparison with the other progressive myoclonus epilepsies. Brain 112:1261-1276
35. Berkovic SF, Carpenter S, Evans A et al (1989) Myoclonus epilepsy and ragged-red fibers (MERRF). 1. A clinical, pathological, biochemical, magnetic resonance spectroscopic and positron emission tomographic study. Brain 112:1231-1260
36. Barkovich AJ, Good WV, Koch TK, Berg BO (1993) Mitochondrial disorders: analysis of their clinical and imaging characteristics. Am J Neuroradiol 14:1119-1137
37. Riggs JE, Shochet SS, Fakaday AV et al (1984) Mitochondrial encephalomyopathy with decreased succinate-cytochrome c reductase activity. Neurology 34:48
38. Boulet L, Karpati G, Shoubridge EA (1992) Distribution and threshold expression of the tRNALys mutation in skeletal muscle of patients with myoclonic epilepsy and ragged-red fibers (MERRF). Am J Hum Genet 51:1187-1200
39. Moraes CT, Ciacci F, Bonilla E et al (1993) Two novel pathogenic mitochondrial DNA mutations affecting organelle number and protein synthesis. J Clin Invest 92:2906
40. Williams RE, Aberg L, Autti T et al (2006) Diagnosis of the neuronal ceroid lipofuscinoses: an update. Biochim Biophys Acta 1762:865-872
41. Autti T, Raininko R, Vanhanen SL, Santavuori P (1996) MRI of neuronal ceroid lipofuscinosis. Part I: cranial MRI of 30 patients with juvenile neuronal ceroid lipofuscinosis. Neuroradiology 38:476-482
42. Autti T, Raininko R, Santavuori P, Vanhanen SL, Poutanen VP, Haltia M (1997) MRI evaluation of neuronal ceroid lipofuscinosis: part II: postmortem MRI and histopathological study of the brain in 16 patients with neuronal ceroid lipofuscinosis of juvenile or late infantile type. Neuroradiology 39:371-377
43. Mole SE, Williams RE, Goebel HH (2005) Correlations between genotype, ultrastructural morphology and clinical phenotype in the neuronal ceroid lipofuscinoses. Neurogenetics 6:107-126
44. Steinfeld R, Heim P, von Gregory H, Meyer K, Ullrich K et al (2002) Late infantile neuronal ceroid lipofuscinosis: quantitative description of the clinical course in patients with CLN2 mutations. Am J Med Genet 112:347-354
45. Holmberg V, Lauronen L, Autti T, Santavuori P, Savukoski M, Uvebrant P et al (2000) Phenotype - genotype correlation in eight patients with Finnish variant late infantile NCL (CLN5). Neurology 55:579-581
46. Santavuori P, Rapola J, Sainio K, Raitta C (1982) A variant of Jansky-Bielschowsky disease. Neuropediatrics 13:135-141
47. Sharp JD, Wheeler RB, Parker KA, Gardiner RM, Williams RE, Mole SE (2003) Spectrum of CLN6 mutations in variant late infantile neuronal ceroid lipofuscinosis. Human Mutat 22:35-42
48. Ranta S, Zhang Y, Ross B, Lonka L, Takkunen E et al (1999) The neuronal ceroid lipofuscinoses in human EPMR and mnd mutant mice are associated with mutations in CLN8. Nat Genet 23:233-236
49. Striano P, Specchio N, Biancheri R, Cannelli N, Simonati A et al (2007) Clinical and electrophysiological features of epilepsy in Italian patients with CLN8 mutations. Epilepsy Behav 10:187-191
50. Hofmann SL, Das AK, Yi W, Lu JY, Wisniewski KE (1999) Genotype-phenotype correlations in neuronal ceroid lipofuscinosis due to palmitoylprotein thioesterase deficiency. Mol Genet Metab 66:234-239
51. Rapin I, Goldfisher S, Katzman R, Engel J, O'Brien JS (1978) The cherry-red spot myoclonus syndrome. Ann Neurol 3:234-242
52. Palmeri S, Villanova M, Malandrini A et al (2000) Type I sialidosis: a clinical, biochemical and neuroradiological study. Eur Neurol 43:88-94
53. Engel J, Rapin I, Giblin D (1977) Electrophysiological studies in two patients with cherry-red spot myoclonus syndrome. Epilepsia 18:73-87
54. Seyrantepe V, Poupetova H, Froissart R, Zabot MT, Maire I, Pshezhetsky AV (2003) Molecular pathology of NEU1 gene in sialidosis. Hum Mutat 22:343-352
55. Tsuji S (2002) Dentatorubral-pallidoluysian atrophy: clinical aspects and molecular genetics. Adv Neurol 89:231-239
56. Koide R, Ikeuchi T, Onodera O et al (1994) Unstable expansion of CAG repeat in hereditary dentatorubral-pallidoluysian atrophy (DRPLA). Nat Genet 6:9-13
57. Nagafuchi S, Yanagisawa H, Sato K et al (1994) Expansion of an unstable CAG trinucleotide on chromosome 12p in dentatorubral and pallidoluysian atrophy. Nat Genet 6:14-18
58. Iivanainen M, Himberg JJ (1982) Valproate and clonazepam in the treatment of severe progressive myoclonus epilepsy. Arch Neurol 39:236-238
59. Tein I, DiMauro S, Xie Z-W, De Vivo DC (1993) Valproic acid impairs carnitine uptake in cultured human skin fibroblasts: an in vitro model for pathogenesis of valproic acid-associated carnitine deficiency. Pediatr Res 34:281-287
60. Remy C, Genton P (1991) Effect of high dose of oral piracetam on myoclonus in progressive myoclonus epilepsy (Mediterranean myoclonus). Epilepsia 32:6
61. Magaudda A, Gelisse P, Genton P (2004) Antimyoclonic effect of levetiracetam in 13 patients with Unverricht-Lundborg disease: clinical observations. Epilepsia 45:678-681
62. Eldridge R, Iivanainen M, Stern R, Koerber T, Wilder BJ (1983) "Baltic" myoclonus epilepsy: hereditary disorder of childhood made worse by phenytoin. Lancet 2(8354):838-842
63. Smith B, Shatz R, Elisevich K, Bespalova IN, Burmeister M (2000) Effects of vagus nerve stimulation on progressive myoclonus epilepsy of Unverricht-Lundborg type. Epilepsia 41:1046-1048
64. Kyllerman M, Ben-Menachem E (1998) Zonisamide for progressive myoclonus epilepsy: long-term observations in seven patients. Epilepsy Res 29:109-114
65. Vossler DG, Conry JA, Murphy JV, ZNS-502/505 PME Study Group (2008) Zonisamide for the treatment of myoclonic seizures in progressive myoclonic epilepsy: an open-label study. Epileptic Disord 10(1):31-34
66. DiMauro S, Hirano M, Schon EA (2000) Mitochondrial encephalomyopathies: therapeutic approaches. Neurol Sci 21(suppl 5):S901-S908